About Vacuolar protein sorting-associated protein 26A
Vacuolar protein sorting-associated protein 26A (VPS26A) is a protein
from Homo sapiens identified by UniProt accession
O75436, 327 residues long.
MolForge cross-references it against 0 known binders and
52 disease associations.
Target properties
| Protein name | Vacuolar protein sorting-associated protein 26A |
|---|
| UniProt accession | O75436 |
|---|
| Gene | VPS26A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 327 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (52)
Diseases linked to this target (Open Targets).
- basophil count · score 0.34
- basophil percentage of leukocytes · score 0.28
- cytokine measurement · score 0.13
- response to vaccine · score 0.13
- type 2 diabetes mellitus · score 0.13
- platelet component distribution width · score 0.11
- pancreatic adenocarcinoma · score 0.07
- testosterone measurement · score 0.06
- lymphocyte count · score 0.06
- eosinophil percentage of leukocytes · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75436-F1 | alphafold | PREDICTED | 87.67 | — |
Amino-acid sequence (327 residues)
MSFLGGFFGP ICEIDIVLND GETRKMAEMK TEDGKVEKHY LFYDGESVSG KVNLAFKQPG KRLEHQGIRI EFVGQIELFN DKSNTHEFVN LVKELALPGE LTQSRSYDFE FMQVEKPYES YIGANVRLRY FLKVTIVRRL TDLVKEYDLI VHQLATYPDV NNSIKMEVGI EDCLHIEFEY NKSKYHLKDV IVGKIYFLLV RIKIQHMELQ LIKKEITGIG PSTTTETETI AKYEIMDGAP VKGESIPIRL FLAGYDPTPT MRDVNKKFSV RYFLNLVLVD EEDRRYFKQQ EIILWRKAPE KLRKQRTNFH QRFESPESQA SAEQPEM
Explore Vacuolar protein sorting-associated protein 26A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets